Daniel Sorobetea
- Department of Microbiology, Tumor and Cell Biology
- Division of Host-Microbe
- Biology of Plasmodium Falciparum – The Mats Wahlgren Group
Research
Microbial pathogens claim the lives of millions of people worldwide each year, while millions more suffer from chronic infections. Increases in antibiotic resistance threaten to undermine already limited treatment options, highlighting an urgent need for new therapeutic approaches. I seek to uncover the fundamental immune mechanisms of pathogen restriction, with the ultimate goal of developing new vaccines and therapies against infectious diseases.
Some infectious microbes have evolved to subvert host immunity, resulting in chronic disease. In these contexts, immune cells adopt an alternative strategy by surrounding and trapping the pathogens within structures called granulomas, temporarily preventing further spread and organ damage. Although generally considered protective, these immune structures also provide a niche from which pathogens can spread should the immune system be compromised, the primary example being reactivation of tuberculosis in patients suffering from AIDS. Granulomas occur in a vast array of diseases from leishmaniasis and histoplasmosis to Hodgkin’s lymphoma and Crohn’s disease. However, despite their long history in histopathologic literature and importance in infectious disease, granulomas pose a problem in clinical settings due to the lack of therapeutic approaches that eradicate pathogens within these structures. Progress has been hampered in large part due to our limited understanding of the basic mechanisms at play, as well as the lack of reliable animal models that faithfully capture the symptoms observed in humans.
Yersinia pseudotuberculosis is a bacterial pathogen that colonizes the intestinal tract of both humans and rodents, causing gastroenteritis and lymphadenopathy. I recently identified granulomas as a niche for Yersinia invasion in the mouse intestine and demonstrated that monocytes and neutrophils of the innate immune system are essential for maintenance of intact granulomas and bacterial restriction, providing a novel tool to dissect the mechanistic basis of granuloma biology.
I am currently exploring how intestinal granulomas are sterilized and cleared. Understanding this process may enable host-directed approaches to enhance immunity against pathogens that are resistant to antibiotics and alleviate granulomatous diseases. I ecnourage those who are interested in pursuing exciting research at the interface between immunology and microbiology to contact me for available positions.
Teaching
Teaching and mentoring are great passions of mine and I currently lecture at the following courses:
BIOR88 - Immunology and Infection Biology - Lund University
4BI107 - Frontiers in Biomedicine - Karolinska Institutet
C1F3114 - Molecular Immunology - Karolinska Institutet
Throughout my scientific journey, I have had the opportunity to work with students from many different backgrounds, and have learned that there is no one-size-fits-all approach to mentoring. Rather, it needs to be tailored to the needs and goals of the individual and I believe that people perform at their best when they can follow their own path. My mentorship thus aims to empower trainees to steer their projects in the direction that they are passionate about and provide guidance in a way that resonates with them.
Articles
- Journal article: MBIO. 2025;:e0177925Peterson ST; Dailey KG; Hullahalli K; Sorobetea D; Matsuda R; Sewell J; Yost W; O'Neill R; Bobba S; Apenes N; Sherman ME; Balazs GI; Assenmacher C-A; Cox A; Lanza M; Shin S; Waldor MK; Brodsky IE
- Journal article: BIORXIV. 2025;:2025.02.26.639286Peterson ST; Dailey KG; Hullahalli K; Sorobetea D; Matsuda R; Sewell J; Yost W; Neill RO; Bobba S; Apenes N; Sherman ME; Balazs GI; Assenmacher C-A; Cox A; Lanza M; Shin S; Waldor MK; Brodsky IE
- Article: SCIENCE ADVANCES. 2024;10(30):eadl3629Wertman RS; Yost W; Herrmann BI; Bourne CM; Sorobetea D; Go CK; Saller BS; Groß O; Scott P; Rongvaux A; Taabazuing CY; Brodsky IE
- Article: JOURNAL OF EXPERIMENTAL MEDICINE. 2024;221(3):e20230679Matsuda R; Sorobetea D; Zhang J; Peterson ST; Grayczyk JP; Yost W; Apenes N; Kovalik ME; Herrmann B; O'Neill RJ; Bohrer AC; Lanza M; Assenmacher C-A; Mayer-Barber KD; Shin S; Brodsky IE
- Article: NATURE MICROBIOLOGY. 2023;8(4):666-678Sorobetea D; Matsuda R; Peterson ST; Grayczyk JP; Rao I; Krespan E; Lanza M; Assenmacher C-A; Mack M; Beiting DP; Radaelli E; Brodsky IE
- Article: SCIENTIFIC REPORTS. 2021;11(1):13485Hamza KH; Dunér E; Ulmert I; Arias A; Sorobetea D; Lahl K
- Article: NATURE COMMUNICATIONS. 2019;10(1):1729Dondelinger Y; Delanghe T; Priem D; Wynosky-Dolfi MA; Sorobetea D; Rojas-Rivera D; Giansanti P; Roelandt R; Gropengiesser J; Ruckdeschel K; Savvides SN; Heck AJR; Vandenabeele P; Brodsky IE; Bertrand MJM
- Article: SCIENTIFIC REPORTS. 2017;7:44571Withers SB; Forman R; Meza-Perez S; Sorobetea D; Sitnik K; Hopwood T; Lawrence CB; Agace WW; Else KJ; Heagerty AM; Svensson-Frej M; Cruickshank SM
- Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2017;47(2):257-268Sorobetea D; Holm JB; Henningsson H; Kristiansen K; Svensson-Frej M
- Article: PLOS ONE. 2015;10(5):e0125495Holm JB; Sorobetea D; Kiilerich P; Ramayo-Caldas Y; Estellé J; Ma T; Madsen L; Kristiansen K; Svensson-Frej M
All other publications
- Review: MUCOSAL IMMUNOLOGY. 2018;11(2):304-315Sorobetea D; Svensson-Frej M; Grencis R
Grants
- Swedish Research Council1 January 2024 - 31 December 2027Microbial pathogens claim the lives of millions of people worldwide each year, while millions more suffer from chronic infections. Increases in antibiotic resistance threaten to undermine already limited treatment options, highlighting an urgent need for new therapeutic approaches. Granulomas act as barriers to pathogen dissemination and form in response to a wide variety of infections, such as histoplasmosis, leishmaniasis and tuberculosis. Although generally considered protective, these immune structures also provide a replicative niche from which pathogens can spread should the immune system be compromised. A major unanswered question has been how granulomas are sterilized and cleared. Solving this problem would enable us to alleviate granulomatous diseases. Yet, the molecular basis of pathogen restriction within granulomas remains poorly understood.I recently identified granulomas as an unappreciated niche for enteropathogenic Yersinia invasion in the murine intestine. My new preliminary data reveal that intestinal granulomas are sterilized by T lymphocytes, providing a novel tool to dissect the mechanistic basis of granuloma resolution. With my experience in mucosal immunology and microbial pathogenesis, I aim to dissect how T cells orchestrate granuloma resolution to facilitate bacterial control. Altogether, this proposal seeks to uncover fundamental mechanisms of pathogen restriction, with the long-term goal of developing new treatments for granulomatous diseases.
- Jaensson FoundationMicrobial pathogens claim the lives of millions of people worldwide each year, while millions more suffer from chronic infections. Increases in antibiotic resistance threaten to undermine already limited treatment options, highlighting an urgent need for new therapeutic approaches. Chronic granulomatous diseases account for a substantial proportion of both infectious and non-infectious diseases but have been notoriously difficult to treat in the clinic. This is in large part due to our limited understanding of the basic mechanisms at play, as well as the lack of tractable animal models that faithfully recapitulate the symptoms observed in humans. I recently identified granulomas as a niche for enteropathogenic Yersinia invasion in the murine intestine and demonstrated that monocytes and neutrophils of the innate immune system are essential for maintenance of intact granulomas. My new preliminary studies reveal that intestinal granulomas are sterilized by T lymphocytes, providing a novel tool to dissect the mechanistic basis of granuloma resolution. Based on my published and preliminary work, I hypothesize that T cells orchestrate intestinal granuloma resolution by enabling monocytes and neutrophils to overcome Yersinia blockade of host defense. Leveraging these immune pathways will enable us to treat infectious pathogens that are otherwise resistant to antibiotics and alleviate disease in humans.
- Defining protective immunity within granulomas during enteric infectionKarolinska Institutet Research Foundation
- Magnus Bergvall FoundationGranulomas are chronic immune structures that form in a wide range of diseases, from tuberculosis and histoplasmosis to sarcoidosis and Crohn's disease. Granulomas provide a niche where microbes are sheltered from antibiotics and can survive indefinitely. An important but unanswered question is how they can be sterilized. If we solve this problem, we could alleviate granulomatous diseases and eradicate chronic infections. Despite their importance in many diseases, granulomas pose a problem in clinical settings, both due to the lack of treatments that can be used against these structures and a lack of understanding of their basic biology. I have established a mouse model where granulomas naturally resolve after a bacterial infection affecting humans. With the help of modern genetic tools, I will investigate how intestinal granulomas form, function and dissolve, enabling analysis of the immune mechanisms required for the treatment of infectious granulomas. Understanding how immune cells can sterilize granulomas, and in particular why this often fails, will lay the foundation for new therapies to reduce the suffering of patients with chronic diseases. All in all, this project aims to uncover fundamental mechanisms of control of pathogenic organisms, with the long-term goal of developing new treatments for chronic granulomatous diseases and antibiotic-resistant microbes.
Employments
- Assistant Professor, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2024-2028
- Postdoctoral fellowship, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 2018-2024
Degrees and Education
- PhD in immunology, Section for Immunology, Medical Faculty, Lund University, 2017